2 results for “Cancer-clinic suppression claims by treatment type”
Claims that clinics, regulators, or pharmaceutical companies suppress alternative cancer cures.
Two opposing suppression narratives circulate about pediatric gender-affirming care. The first holds that established, evidence-based care is being suppressed by transphobic state legislation (partially supported: more than 20 US states have enacted restrictions or bans since 2021). The second holds that the evidence base for pediatric transition interventions is itself weaker than advocacy bodies have claimed, and that clinicians and medical associations have suppressed this uncertainty (partially supported: the UK's independent Cass Review, published April 2024, found the evidence base "remarkably weak" and recommended a more cautious, individualized approach). This is a contested, ongoing medical-evidence debate with real factual stakes on multiple sides.